New York: American Pfizer and Moderna drug makers have, in different studies, claiming that the protection of their MRNA vaccine against Covid-19 can last only about six months, or a little more, throwing a strong case for booster shots, ignoring the call against it by Many scientists.
On Wednesday, Moderna in a new analysis of the Three phase study indicated that the low dose of the vaccine lasted only six months.
The findings show that the incidence of Covid Cases of breakthrough is less rare in more recent participants inoculated, indicating that immunity for people who were vaccinated before began to decrease.
Of the 11,431 people who were vaccinated between December and March, 88 was identified as a breakthrough case compared to 162 breakthrough cases from 14,746 trial participants vaccinated in July to October last year, the company said in the release.
“Increased risk of breakthrough infection in participants vaccinated last year compared to more recently illustrating the impact of reduced immunity and supporting the need for booster to maintain a high level of protection,” said CEO of Modernan Stephane Bancel in a statement.
Likewise, on Wednesday, Pfizer cited Israel’s data to make cases on US food and drug administration for booster.
The US drug giant argued that the third dose of the Covid vaccine was six months after the second shot restored protection from infection of up to 95%, CNBC reported.
While the effectiveness of the MRNA vaccine decreases from time to time, Booster’s shot has been shown to cause an immune response similar to the protection produced after the second dose, said Pfizer in a presentation of 52 pages delivered to the US FDA.
While many countries such as Israel, UAE, Russia, France, Germany and Italy have continued with a booster dose, many scientists oppose third covid shots.
Last week, the CEO of Astrazeneca Pascal Soriot wrote on the telegraph that the third dose of vaccines against Covid-19 may not be needed for everyone.
He stated that the decision to stay the entire population must be based on “real-world clinical effectiveness data, not just an antibody measurement”.
In a recent review published in Lancet, a group of international scientists argued that the efficacy of the vaccine against severe Covid was very high, even for the Delta variant, that the dose of booster for the general population “was not appropriate” at this stage in a pandemic.
They reaffirmed the concern submitted by the World Health Organization (WHO) on vaccine inequality by rich countries.
Meanwhile, which calls for a global moratorium extension at the Covid-19 booster dose, with the aim of allowing every country to vaccinate at least 40% of the population.